ProQR Therapeutics N.V.

Factors to consider:

• Total employees count: 59 as of 2014
• Price in estimated range
• Earnings for 3 months up through Q1 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2025-12-31 to 2027-12-31

• 2025-12-31 to 2026-12-31 estimated range: [1.44$, 3.29$]
• 2026-12-31 to 2027-12-31 estimated range: [1.37$, 3.18$]

Financial Metrics affecting the PRQR estimates:

• Positive: with PPE of -4.6 at the end of fiscal year the price was neutral
• Negative: negative Operating cash flow
• Negative: negative Operating income
• Positive: Investing cash flow per share per price, % of -0.52 > -0.60
• Positive: Interest expense per share per price, % of 0.46 <= 0.73
• Negative: negative Net income
• Positive: 42.59 < Shareholder equity ratio, % of 43.79 <= 64.29
• Positive: Inventory ratio change, % of -53.45 <= -0.75